GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Core Viewpoint - GRI Bio, Inc. is participating in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, to discuss its innovative pipeline of immune cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [1][2]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment of inflammatory, fibrotic, and autoimmune diseases through therapies targeting Natural Killer T (NKT) cells [3]. - The company's lead program, GRI-0621, is an RARβγ agonist aimed at inhibiting iNKT cell activity and is being developed as an oral therapeutic for idiopathic pulmonary fibrosis, a disease with significant unmet needs [3]. - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [3]. Webinar Details - The presentation will take place on February 11, 2026, at 1:00 PM EST, led by Marc Hertz, PhD, the President and CEO of GRI Bio [2].